Karman Holdings Shorts Trim as Analysts Cut Targets Before Earnings

Karman Holdings makes mission-critical structural components and propulsion hardware for missile, space, and maritime defense programs. The stock gained 7.7% on the week to close at $37.73, outpacing a peer median of around 4.7%, yet it remains roughly 50% below where it started the year and earnings land in eight days.

The short-side picture has two layers worth separating. At 12.4% of free float, the short position is substantial and has grown about 3.8% over the past month, so there is real conviction here from bears. But over the past week, shorts actually trimmed by about 1.3%, taking some pressure off. More telling is what has happened to availability in the lending market: it has tightened sharply from around 220% just three weeks ago to 115% now, meaning roughly one share remains available to borrow for every share already lent out. That is a meaningful tightening in a short time, though the borrow itself remains cheap at 0.52% annualised. Options traders hold a put/call ratio of 1.70, slightly above the 20-day average of 1.58 but well within normal range at just 0.56 standard deviations above the mean. The 52-week high on PCR was 5.77, so this does not read as panicked hedging, just cautious positioning into a catalyst.

The Street picture is one of broad bullishness on paper but rapidly declining price targets. Every recent analyst action carries an Outperform, Overweight, or Buy rating, and five firms have initiated or reiterated positive views since September. Yet targets have come down hard. RBC Capital trimmed to $60 this week from $70, itself a cut from $85 in September. Piper Sandler took its target from $91 to $59 last week. Oppenheimer, initiating at $40, effectively anchored at the low end of a wide range that spans $37 to $79. The mean target of $76 looks increasingly like a lagging average weighted by older, pre-cut figures given the pace of reductions over recent weeks. The EV/EBITDA multiple of 20x has barely moved over 30 days, while the P/E of 42x has expanded modestly as the stock drifted off its lows. The ORTEX short score of 68.7, the highest in the past two weeks, reflects an elevated but not extreme short-side signal. Factor scores show strong EPS momentum over 30 and 90 days, but valuation and earnings yield rank in the bottom quartile of the universe, consistent with the bear case centring on cash generation rather than growth.

The ownership register adds context to the week's moves. BlackRock filed a Schedule 13G on October 5 disclosing an 11.1% stake, making it the largest institutional holder by a distance. First Trust Portfolios filed its own 13G just yesterday, disclosing 5.25%. Both are passive disclosures rather than activist positions, and the standard caveat applies: stakes are as last disclosed around the 5% threshold, and holders dropping below that level need not file again. State Street added 2.25 million shares through September. Columbia Management added 1.37 million. On the insider side, the most recent open-market purchase was director David Stinnett buying 27,000 shares at $37.32 on September 16, a transaction worth just over $1 million. Two other directors also bought in small amounts the same day. No insider sales appear in the past 90 days, and net insider buying over that period totals around 27,775 shares. The buys were made around the current price level, which is notable given the stock's longer decline.

The last two earnings reports produced double-digit positive moves. The August 2026 print drove a 12.7% gain on the day and held 12.5% higher five days later. An earlier report produced a 5.6% one-day gain that extended to 9.8% over the following week. The bull case heading into the November 5 print rests on that same organic growth trajectory, a 2.7x book-to-bill ratio, and $1.32 billion of backlog. The bear case focuses on negative operating cash flow in the first half, elevated debt, and three customers accounting for more than half of revenue. With availability tightening, a meaningful short position in place, and analysts converging on a lower but still-bullish target range, the November 5 print will be a direct test of whether 24%-plus organic revenue growth can eventually translate into the free cash flow the valuation currently does not reflect.